Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1021-1040 of 1,307 trials

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Posttraumatic Headache: Botulinum Toxin A Study

We are investigating whether botulinum toxin A can safely reduce the number of headache days for individuals with posttraumatic headaches. The study also looks at biological markers to see if they can predict treatment success.

Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNeurology

Lung Cancer: Pembrolizumab Maintenance Study

We are studying whether continuing pembrolizumab treatment helps patients with stage IV lung cancer maintain disease control after initial chemotherapy. This trial will also look at the quality of life and side effects experienced by participants.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Myelofibrosis: Study of Pacritinib vs. Standard Treatment

We are investigating whether pacritinib can better reduce spleen size and improve symptoms in patients with myelofibrosis. This trial is for those with severe low platelet counts and compares pacritinib to physician's choice of therapy.

Post-Polycythaemia Vera MyelofibrosisPrimary MyelofibrosisPost-Essential Thrombocythaemia Myelofibrosis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Acute Cholecystitis: Antibiotic Treatment Comparison

We are studying whether a single dose of antibiotics before gallbladder surgery is as effective as continuous antibiotics in preventing infections. This trial aims to improve patient outcomes during and after surgery.

Acute Cholecystitis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Generalized Myasthenia Gravis: IMVT-1402 Study

We are testing a new treatment for people with mild to severe generalized myasthenia gravis. The study aims to see if it can improve muscle strength and reduce symptoms.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)Investigational MedicinesCost ReimbursementNeurology

Oligometastatic Peritoneal Gastric Cancer: PIPAC Treatment Study

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard chemotherapy helps patients with oligometastatic peritoneal gastric cancer have better surgery outcomes and longer survival.

Metastatic Gastric Adenocarcinoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Cardiac Arrest: Ketamine vs. Propofol Sedation

We are studying whether ketamine sedation can better protect the brain and improve survival compared to propofol in patients resuscitated from cardiac arrest. This trial looks at outcomes at discharge and 180 days later.

Out-of-Hospital Cardiac Arrest1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Out-of-Hospital Cardiac Arrest: DANOHCA Study

We are testing different treatments, including medications and positioning, for patients who have had a cardiac arrest outside the hospital. Our goal is to see which methods may improve survival and recovery.

Cardiac Arrest>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInternal Medicine

Cardiac Surgery: Dexamethasone and Olanzapine Study

We are investigating whether dexamethasone and olanzapine improve recovery for adults undergoing heart surgery. The study also looks at different management techniques to enhance patient outcomes after surgery.

Ischemic Heart DiseaseHeart Valve Surgery>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInternal Medicine

Myelodysplastic Syndromes: Elritercept Treatment Study

We are testing elritercept to see if it can help reduce the need for blood transfusions in adults with certain types of myelodysplastic syndromes. The study will also look at how safe and tolerable the treatment is.

Myelodysplastic Syndrome (MDS)Anemia6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Huntington's Disease: Innovative Biomarker Study

We are exploring new imaging and cognitive markers to better understand how Huntington's disease progresses. This study aims to identify effective ways to track the disease from early stages.

Huntington's DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Multiple Myeloma: Belantamab Mafodotin vs. Daratumumab

We are studying a new treatment combination for people with newly diagnosed multiple myeloma who cannot have stem cell transplants. The goal is to see if it works better and is safer than the current standard treatment.

Multiple MyelomaConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Migraine Aura: Amiloride Study

We are investigating whether amiloride can help prevent migraine aura and headaches in people who experience these symptoms. The study will also assess the safety of this medication.

Migraine Aura6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInternal MedicineNeurology

Hydroxychloroquine for Early Systemic Sclerosis

We are studying whether adding hydroxychloroquine to standard treatments helps improve symptoms in people with early systemic sclerosis. The trial will assess its safety and effectiveness compared to a placebo.

Systemic Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineRheumatology

Kamada-AAT for Inhalation in Alpha-1 Antitrypsin Deficiency

We are studying a new inhalation treatment for adults with congenital Alpha-1 Antitrypsin Deficiency to see if it improves lung function compared to a placebo. The trial also looks at safety and immune responses to the treatment.

Congenital Alpha-1 Antitrypsin Deficiency>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Severe Influenza: Early Oseltamivir Carboxylate Levels

We are studying how low levels of oseltamivir carboxylate in critically ill patients with severe influenza affect their recovery and survival. This research may help improve treatment for patients in intensive care.

Severe Influenza Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine